Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 559-561, 2006; 10.1373/clinchem.2005.064766
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baxter-Lowe, L. A.
Right arrow Articles by Busch, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baxter-Lowe, L. A.
Right arrow Articles by Busch, M. P.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2006;52:559-561.)
© 2006 American Association for Clinical Chemistry, Inc.

Editorials

Tracking Microchimeric DNA in Plasma to Diagnose and Manage Organ Transplant Rejection

Lee Ann Baxter-Lowe1 and Michael P. Busch2,3,a

1 Immunogenetics and Transplantation Laboratory and
2 Blood Systems Research Institute San Francisco, CA
3 Department of Laboratory Medicine University of California San Francisco, CA

aAddress correspondence to this author at: Blood Systems Research Institute, 270 Masonic Ave., San Francisco, CA 94118. Fax 415-775-3859; e-mail MBusch@bloodsystems.org.

The first 300 words of the full text of this article appear below.

One of the most promising areas of transplantation research is the recent discovery of biomarkers for rejection that are detectable in blood and urine. Biopsy-confirmed rejection, the current gold standard for diagnosis of allograft rejection, is invasive and subject to sampling errors. For example, diagnosis of episodes of rejection of pancreas allografts, which are frequent and can destroy the allograft, depends on conventional percutaneous biopsies that have a diagnostic sensitivity of only 79%–88% (1)(2) and are associated with a 2%–7% risk of serious complications (3). Development of noninvasive assays that detect molecular biomarkers for rejection could revolutionize management of transplant recipients by (a) detecting a prerejection profile that will allow therapeutic interventions before rejection causes graft dysfunction; (b) improving the sensitivity and specificity of rejection diagnosis; (c) developing new classification systems for rejection that will improve prognosis; and (d) providing information for designing individualized immunosuppressive regimens that could prevent rejection while minimizing drug toxicity.

There have been several exciting reports of potential biomarkers for allograft rejection, with the most significant progress occurring in the area of renal transplantation. This work began by studying concentrations of particular mRNAs or proteins that were associated with immune activation or tissue stress (4). These studies have revealed several gene products that have altered expression in blood, urine, and/or biopsy tissue during rejection episodes. In the most recent contribution in this rapidly evolving field, Muthukumar et al. (5) demonstrated that urine concentrations of FOXP3 mRNA, a member of the forkhead family of cell differentiation genes and a lineage-specific transcript for graft-protecting regulatory T cells, can predict reversal of acute renal allograft rejection with 90% sensitivity and 73% specificity. Although measurement of the products of individual genes such . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.